<DOC>
	<DOCNO>NCT00907803</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics two clinical dos anti-orthopoxvirus drug , ST-246 , administer single daily oral dose 14 day healthy , fed volunteer . The result trial determine dose use expand pivotal safety trial .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ( PK ) Anti-Orthopox Drug , ST-246</brief_title>
	<detailed_description>This study Phase II , double-blind , randomize , placebo-controlled , multi-center ( 3 site ) trial ass safety , tolerability , pharmacokinetics 400 mg 600 mg Form I ST-246 administered single daily oral dose 14 day 107 healthy , fed volunteer 18 74 year age . Safety parameter include adverse event , vital sign , physical examination , laboratory test ( hematology , blood chemistry , urinalysis ) electrocardiogram .</detailed_description>
	<criteria>1 . 18 75 yr 2 . Healthy volunteer 3 . Ability consent 4 . Available clinical followup study 5 . Not take medication 6 . Adequate venous access 7 . Using adequate birth control ; negative pregnancy test 8 . Able willing avoid alcohol screen study duration 1 . Inability swallow study medication 2 . Pregnant breastfeed 3 . Medical condition , e.g. , asthma , hypertension , angioedema , traumatic brain injury concussion , bleed disorder , blood dyscrasia , idiopathic seizure , cardiac disease limit activity , diabetes , active malignancy , Hepatitis B C , HIV AIDS , chronic microbial infection , 4 . History drug allergy contraindicates study participation 5 . Medical , psychiatric , social , occupational reason jeopardizes safety/rights participant render he/she unable comply protocol ( include drug alcohol abuse , homelessness ) 6 . Clinically abnormal ECG 7 . Has participate clinical trial experimental treatment within 30 day , , study 8 . Can physical exercise 24 hr PK day 9 . Will consume grapefruit/grapefruit juice study 10 . Vaccination within 2 wks screen , plan Day 42 study 11 . Treatment prednisone equivalent immunosuppressant/modulatory drug &lt; 3 mths screen 12 . Clinically significant physical exam lab result &lt; 2weeks 1st study drug dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Orthopoxvirus</keyword>
	<keyword>Smallpox</keyword>
	<keyword>This safety study</keyword>
	<keyword>ST-246 study treatment Orthopoxviruses</keyword>
</DOC>